-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

906.O2.6 906. Outcomes Research—Myeloid Malignancies II

Symposia: Outcomes Research—Myeloid Malignancies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Acute Myeloid Malignancies, Biological therapies, AML, MDS, adult, Clinical Practice (Health Services and Quality), epidemiology, elderly, Clinical Research, health outcomes research, Diversity, Equity, and Inclusion (DEI) , Chronic Myeloid Malignancies, Diseases, Therapies, real-world evidence, Adverse Events, registries, Myeloid Malignancies, survivorship, Study Population, Human, Transplantation
Saturday, December 10, 2022: 2:00 PM-3:30 PM
220-222 (Ernest N. Morial Convention Center)
Rebecca L. Olin, MD, University of California, San Francisco and Eduardo M Rego, MD, PhD, University of São Paulo
Olin: Cellectis: Other: NA; Astellas: Consultancy; Actinium: Consultancy; Abbvie: Consultancy.
Studies focusing real-world outcomes, healthcare services utilization and evaluation of risk in myeloid malignancies
2:00 PM

Pankit Vachhani, MD1, Esprit Ma, MPH2*, Tao Xu, PhD3*, Melissa Montez, PharmD4*, Sarah Worth, PharmD1*, Wei-Han Cheng, PhD5*, Michael Werner, PhD5*, Jonathan Abbas, MD6 and William Donnellan, MD6

1O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, AL
2Genentech, Inc., South San Francisco, CA
3F. Hoffmann-La Roche Ltd, Basel, Switzerland
4Genentech, South San Francisco, CA
5AbbVie, Inc., North Chicago, IL
6Tennessee Oncology, Nashville, TN

2:15 PM

Karen K. Ballen, MD1, Tao Wang, PhD2,3*, Naya He, MPH2*, Shahrukh Hashmi, MD, MPH4,5*, Leslie E. Lehmann, MD6, William A. Wood, MD, MPH7, Hemalatha G. Rangarajan, MD8 and Wael Saber, MD, MS2

1Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA
2CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
3Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI
4Department of Internal Medicine, Mayo Clinic, Rochester, MN
5Department of Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates
6Dana Farber Cancer Institute/Boston Children's Hospital, Boston, MA
7Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC
8Division of Hematology, Oncology, Blood and Marrow Transplant, Nationwide Childrens Hospital, Columbus, OH

2:30 PM

Julia H. Joo1, Yanwen Chen, PhD2*, Aaron T. Gerds, MD, MS3, Anjali Advani, MD4, Sophia R. Balderman, MD5, Hetty E. Carraway, MD, MBA6, Abhay Singh, MD, MPH7 and Sudipto Mukherjee, MD, PhD, MPH6

1Cleveland Clinic Lerner College of Medicine, Cleveland, OH
2Quantitative Health Sciences, Cleveland Clinic, Cleveland
3Department of Hematology and Medical Oncology,, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
4Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
5Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
6Department of Hematology and Medical Oncology, Taussig Cancer institute, Leukemia Program, Cleveland Clinic, Cleveland, OH
7Taussig cancer center, Cleveland Clinic, Cleveland clinic, Cleveland, OH

2:45 PM

Anna Sophia Moret1*, Eva Telzerow1*, Maria Cristina Sauerland, MSc2*, Simon M. Krauss3*, Maja Rothenberg-Thurley4*, Friederike H. A. Mumm, MD1*, Jan Braess, MD5*, Bernhard J. Wörmann, MD6*, Utz Krug, MD7, Wolfgang E. Berdel, MD8, Wolfgang Hiddemann, MD, PhD1, Karsten Spiekermann1, Pia Heußner, MD9*, Dennis Görlich, PhD10* and Klaus H. Metzeler, MD3

1Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany
2Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany
3Department of Hematology, Cell Therapy and Hemostaseology, University Hospital Leipzig, Leipzig, Germany
4Laboratory for Leukemia Diagnostics, Department of Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany
5Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany
6Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany
7Department of Medicine III, Hospital Leverkusen, Leverkusen, Germany
8Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
9Departement of Internal Medicine, Hospital Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany
10Institute of Biostatistics and Clinical Research, University of Muenster, Münster, Germany

3:00 PM

Rohit Singh, MD1*, David Alfonso Alejos Castillo, MD1*, Akshee Batra, MBBS2*, Andrew D Sparks, MS3*, Aditi Shastri, MD4, Kith Pradhan, PhD5*, Neil Zakai6 and Diego Adrianzen Herrera, MD6

1University of Vermont Medical Center, Burlington, VT
2University of Vermont Medical Center, Winooski, VT
3Biomedical Statistics Research Core at the University of Vermont, Burlington, VT
4Department of Oncology, Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY
5Department of Epidemiology & Population Health, Albert Einstein College of medicine, Bronx, NY
6Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT

3:15 PM

Dipenkumar Modi, MD1, Maya Shatta, M.D.2*, Seongho Kim, Ph.D2*, Abhinav Deol, MD1, Andrew Kin, MD1, Asif Alavi, MD1, Lois Ayash, MD1, Voravit Ratanatharathorn, MD1 and Joseph P. Uberti, M.D., Ph.D.1

1Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI
2Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI

*signifies non-member of ASH